MDxHealth SA filings document a foreign private issuer focused on precision diagnostics for prostate cancer and other urologic diseases. The company’s Form 6-K reports furnish financial results, interim reports, press releases, governance updates and materials incorporated by reference into registration statements.
The filing record includes shareholder meeting notices, proxy and attendance materials, a share option plan, authorized-capital reports, warrant terms and acquisition-related disclosures. MDXH filings also document the completed Exosome Diagnostics acquisition through audited financial statements and pro forma financial information, along with amendments to earnout obligations related to the GPS acquisition.
MDxHealth SA director Michael Holder received a grant of share options as compensation. He was awarded options to purchase 10,000 ordinary shares at an exercise price of $0.76 per share, vesting in full on the date of the annual general shareholders' meeting in the calendar year after the grant. Following this grant, he holds 10,000 share options directly, which expire on May 28, 2036. This is a routine equity incentive award rather than an open-market trade.
MDxHealth SA director Sanford Jay Siegel received a grant of share options covering 10,000 ordinary shares. The options have an exercise price of $0.76 per share and were granted as compensation. They vest in full at the annual general shareholders' meeting held in the calendar year after the grant.
Hoffman Koen reported acquisition or exercise transactions in this Form 4 filing.
MDxHealth SA director Koen Hoffman reported a compensation-related grant of share options held indirectly through Ahok BV. The award covers 10,000 options, each exercisable into one ordinary share at $0.76 per share, expiring on May 28, 2036.
The options were granted on June 1, 2026 and vest in full on the date of the annual general shareholders' meeting held in the calendar year after the grant year. The options are held by Ahok BV, of which Hoffman owns 53.33%, and he disclaims beneficial ownership beyond any pecuniary interest.
MDxHealth SA officer Brendan O’Connell, VP of Finance and Accounting, filed a Form 3 as an initial statement of beneficial ownership. The filing lists him as an officer of the company and shows no reportable purchases, sales, exercises, gifts, or other transactions in this report.
MDxHealth reported Q1 2026 revenue of $27.4M, up 13% from Q1 2025, driven by its precision oncology portfolio. Gross profit rose to $16.6M, but higher operating expenses of $23.9M led to an operating loss of $7.3M and net loss of $8.9M, or $0.17 per share.
The company will discontinue its Resolve UTI business and close the Plano, Texas lab to refocus on prostate cancer diagnostics and the ExoDx acquisition. It issued new 2026 core cancer revenue guidance, excluding Resolve, of $110–115M, implying 20–26% year‑over‑year growth versus 2025 core cancer revenue.
Cash and cash equivalents were $43.2M as of March 31, 2026; on a pro‑forma basis after a $15.0M 2025 earnout payment to Exact Sciences, cash would have been $28.2M. MDxHealth also received a Medicare contractor recoupment decision of about $10.4M tied to historical Resolve claims, which it is contesting and has recorded as a contingent liability rather than a provision.
MDxHealth is calling ordinary and extraordinary shareholder meetings on May 28, 2026 in Ghent to approve its 2025 accounts, board mandates and auditor renewal, and to vote on several capital measures. The company proposes issuing 3,000,000 new “2026 Exact Sciences Warrants” to a subsidiary of Exact Sciences at an exercise price of USD 5.265 per share, exercisable until January 8, 2031. It also seeks approval for 3,000,000 “2026 Share Options” under a new 2026 Share Option Plan for employees, with a 10‑year term. In addition, the board asks shareholders to renew its authorized capital so it may increase share capital by up to 100% of current share capital over five years, including with the ability to restrict or cancel preferential subscription rights where allowed by law.
MDxHealth SA director Eric Bednarski filed an initial Form 3 reporting indirect holdings of 4,700,457 ordinary shares. These shares are directly owned by private investment funds managed by MVM Partners, LLC, where Bednarski is a managing member. He disclaims beneficial ownership beyond any pecuniary interest described in the footnote.
MDxHealth SA Chief Commercial Officer John Bellano filed an initial statement of beneficial ownership showing multiple share option awards over ordinary shares. The filing lists option grants from June 2019 through March 2025, with exercise prices ranging from 12.40 Euros to $1.47 per share and expirations between 2029-07-24 and 2035-04-11.
Several grants vest in three equal installments on each of the first three anniversaries of the grant date, while others vest upon the achievement of Company performance criteria evaluated by the Board of Directors at the end of specified performance periods. All positions are reported as held directly and relate to options, not current share trades.
MDxHealth SA director and Chief Executive Officer Michael McGarrity filed an initial ownership report showing his equity position in the company. The filing lists direct holdings of 95,000 Ordinary Shares and multiple share option awards over additional Ordinary Shares.
The options cover various grants that generally vest in three equal installments over three years or upon achievement of specified company performance criteria, with exercise prices ranging from €2.90–€14.90 and $1.47–$2.62, and expiration dates between 2029 and 2035. This Form 3 is a baseline disclosure and does not report new purchases or sales.
MDxHealth SA officer Joseph Sollee filed an initial Form 3 describing his holdings of share options over ordinary shares. The filing lists multiple option grants with varying exercise prices in euros and U.S. dollars, different vesting schedules including performance-based vesting, and expirations extending through 2035.